Improving Adherence with Patient-Centric Formulations
The term “patient centered,” “patient centric,” or “patient centricity” has increasingly grown in use in the scientific community in a wide variety of contexts. Generally, patient centric medicines are recognized as an essential contributor to healthy aging and the overall patient’s quality of life and life expectancy. However, developing patient centric medicines can pose an alternative approach, away from the traditional drug development, scientific process.
Arguably the most significant compliance challenge in older people is polypharmacy, whereas for children the largest barrier is taste. Pharmaceutical technology has progressed rapidly and technologies including FDCs, multi-particulates and orodispersible dosage forms provide unprecedented opportunities to develop novel and appropriate formulations for both old and new drugs. However, it is important for the formulation scientists to work closely with patients, carers and clinicians to develop such formulations for both the paediatric and geriatric population.
By way of followup from our recent available presentations on alternative drug delivery approaches, this week’s available download is titled “Improving Adherence with Patient-Centric Formulations” from Ruby Burlage at Merck & Co. This presentation addresses the issue of medication non-adherence and multidimensional factors impacting patient adherence. It also discusses pharmaceutical product design based on target patient profile, the impact of non-adherence on treatment outcomes in diabetes, understanding dosing patterns coupled with patient engagement and the opportunity for patient-centered product design for delivery of biologics.
Our goal is to help you improve the performance of your drug products. Would you like to learn new strategies to improve patient compliance, bioavailability, stability and efficacy, all while reducing dosage, cost and decreasing time-to-market?
Don’t miss your opportunity to join industry’s leading drug development innovators and experts at the 2021 Controlled & Modified Drug Release (CR7) & 2021 Peptide Drug Design & Delivery (PEP5) Summits, and walk away with 2 years worth of new product development strategies in just 3 days!
This industry-leading event will bring together key decision makers and innovators within this rapidly growing space. By attending this unique event, you will learn directly from industry’s leading experts and hear unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies and methods in improving drug release mechanisms, maximizing exposure, and reducing time-to-market. Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.
Why consider attending the CR7 & PEP5 Summits?
- 60+ leading industry-led speaker faculty over 3 full days sharing innovative drug development take-home strategies
- 14+ hours of networking and breakout sessions, including evening cocktail reception
- 160+ senior participants senior participants spanning pharma, biotech and specialty delivery and formulation providers
- 2 Events for the Price of 1! Attendees gain access to both events and all networking receptions / tech showcase exhibits for one registration. Group discounts available also!
- Dynamic exhibit hall with multiple leading formulation and drug delivery technology experts
Join over 1250 senior drug product development professionals in our free Novel Drug Discovery & Development Group. Members of this rapidly growing group will benefit by gaining access to an exclusive network of industry and academic professionals within the drug development arena. Members specialize in discovery, development, formulation, delivery and commercialization of innovative drug products.
Want to hear multiple weekly drug product development strategies and approaches from leading organizations and experts? Subscribe here and receive new podcast episodes, presentations, white papers, tips and resources directly from Curtis & Coulter weekly to your inbox